High-frequency repetitive transcranial magnetic stimulation in patients with primary trigeminal neuralgia
10.3760/cma.j.issn.1671-8925.2019.03.010
- VernacularTitle:高频重复经颅磁刺激治疗原发性三叉神经痛的临床研究
- Author:
Xiangyang TANG
1
;
Liangjin YUAN
;
Zuosheng CHEN
Author Information
1. 安徽医科大学附属安庆医院神经内科
- Keywords:
High repetitive transcranial magnetic stimulation;
Primary trigeminal neuralgia;
Clinical efficacy;
Safety
- From:
Chinese Journal of Neuromedicine
2019;18(3):273-277
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the efficacy and safety of high-frequency repetitive transcranial magnetic stimulation (hrTMS) in treatment of patients with primary trigeminal neuralgia. Methods Thirty-eight patients with primary trigeminal neuralgia were divided into hrTMS treatment group and control group (n=19) according to the willing of the patients; patients in the hrTMS treatment group were treated with 20 Hz hrTMS; those in the control group were given placebo-controlled transcranial magnetic stimulation. The visual analogue scale (VAS) scores one week before, and one, two and 4 weeks after treatment were compared between the two groups. Scores of pain scale of Barrow Neurologic Institute (BNI), evoked potential (N100) amplitude and incidence of adverse reactions one, two and 4 weeks after treatment were compared between the two groups. Results VAS scores in the hrTMS treatment group two and 4 weeks after treatment were significantly lower as compared with those in the control group (P<0.05). In patients from the hrTMS treatment group, VAS scores two and 4 weeks after treatment were significantly lower than those one week before and one week after treatment (P<0. 05); and those 4 weeks after treatment were significantly lower than those two weeks after treatment (P<0.05). Patients from the hrTMS treatment group two and 4 weeks after treatment had significantly lower BNI scores and statistically higher N100 amplitude as compared with those in the control group (P<0.05). In the hrTMS treatment group, BNI scores gradually decreased and N100 amplitude gradually increased one, two and 4 weeks after treatment, with statistically significant differences between each two time points (P<0.05). There were no significant differences in the incidence of headache (10.53％ vs. 21.05％) and head discomfort (36.84％ vs. 26.32％) after treatment between the two groups (P>0.05).Conclusion The hrTMS can effectively alleviate pain of primary trigeminal neuralgia, and it is safe and reliable.
